Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 15, Issue 16, Pages 1985-1999
Publisher
Future Medicine Ltd
Online
2014-12-19
DOI
10.2217/pgs.14.140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib
- (2014) You-Bing Zheng et al. MEDICAL ONCOLOGY
- Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer
- (2014) Byeong Seok Sohn et al. ONCOLOGY
- Polymorphism in THBS1 Gene Is Associated with Post-Refractive Surgery Chronic Ocular Surface Inflammation
- (2014) Laura Contreras-Ruiz et al. OPHTHALMOLOGY
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGFA and tumour angiogenesis
- (2013) L. Claesson-Welsh et al. JOURNAL OF INTERNAL MEDICINE
- Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
- (2013) Fotios Loupakis et al. PLoS One
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases
- (2012) M. Shibuya JOURNAL OF BIOCHEMISTRY
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
- (2011) Fotios Loupakis et al. BMC CANCER
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
- (2011) A. Gerger et al. CLINICAL CANCER RESEARCH
- 1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab
- (2011) D. Lambrechts et al. EUROPEAN JOURNAL OF CANCER
- 803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
- (2011) E. Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Unknown
- (2011) Reinhold Medina et al. MOLECULAR MEDICINE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle
- (2011) Guido Bocci et al. PHARMACOGENOMICS
- Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer
- (2010) J. Pander et al. ANNALS OF ONCOLOGY
- Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
- (2010) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
- (2010) R. Sridhara et al. JNCI-Journal of the National Cancer Institute
- Shadows of complexity: what biological networks reveal about epistasis and pleiotropy
- (2009) Anna L. Tyler et al. BIOESSAYS
- Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways
- (2009) S.-U. Chen et al. HUMAN REPRODUCTION
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Exploring the Performance of Multifactor Dimensionality Reduction in Large Scale SNP Studies and in the Presence of Genetic Heterogeneity among Epistatic Disease Models
- (2008) Todd L. Edwards et al. HUMAN HEREDITY
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now